Share This

Create Your Own Business Intelligence Website   Input the stock code or the company name     Search   <02179.HK> - JIANGSU RECBIO TECHNOLOGY CO., LTD.    Stock Screener：Biotechnology, Biotechnology HUTCHMED INNOVATIVE PHAR UNI-BIO GROUP KING INTL INV BBI LIFE SCI ESSEX BIO-TECH JACOBIO-B CANBRIDGE-B 3D MEDICINES FUDANZHANGJIANG OCUMENSION-B FRONTAGE 3SBIO IMMUNEONCO-B GENSCRIPT BIO ASCLETIS-B INNOVENT BIO VIVA BIOTECH TOT BIOPHARM-B JUNSHI BIO EVEREST MED-B LAEKNA-B JW THERAP-B BRII-B HBM HOLDINGS-B LEPU BIO-B KEYMED BIO-B BASECARE-B CARSGEN-B MABPHARM-B CLOVER BIO-B ABBISKO-B SIRNAOMICS-B WUXI XDC WUXI BIO BIOCYTOGEN-B MEILLEUREHEALTH WUXI APPTEC GIANT BIOGENE LUZHU BIOTECH-B CUTIA-B YZYBIO-B QYUNS-B HIGHTIDE-B HUA MEDICINE-B CSTONE PHARMA-B HENLIUS TIGERMED SINOMAB BIO-B CT ENTERPRISE AUSTAR JOINN BEIGENE CANSINOBIO SCICLONE PHARMA TRANSCENTA-B AIM VACCINE MEGA GENOMICS HAOHAI BIOTEC ASCENTAGE-B BOAN BIOTECH IMMUNOTECH-B SKB BIO-B ANTENGENE-B GENOR-B HAO WEN HLDGS HK LIFE SCI CRMI PFC DEVICE BIOSINO BIO-TEC NEP INTERLONG CORNERSTONE TEC HUAKANG BIOMED    Basic Datum Company name Lot P/E P/B EPS DPS RECBIO-B 500 -8.33 3.7625 -1.3045 0.0 Profile Information Data Financial Ratios Profit Loss Cash Flow Balance Earnings Dividend    Related links    Related news   ≫More    Company Rating Date Broker Company name Rating Target ≫More    Company performance - Published Date Company name Turnover* Profit* % Dividend ≫More    Comment 2022-03-21　瑞科亦有研發涉及新冠、帶狀皰疹、流感及手足口病的產品。不過大部分均處於臨床I期或II階段，未有確實能推出市場日期。   2022-03-21　江蘇瑞科生物主力於HPV候選疫苗研發，核心產品是一款用於預防子宮頸癌的重組HPV九價疫苗，已處於III期臨床試驗階段。除瑞科，亦有多家本土疫苗企業正佈局九價HPV疫苗，如康樂衛士、萬泰生物、博唯生物的九價HPV疫苗也處於III期臨床階段。      Top Gain / Loss Show All Charts     Value Name Updated Value Change Change % HSI 04-22 09:30 16513.6 ▲ 289.41 ▲ 1.78% RECBIO-B 04-23 15:27 9.15 ▲ 9.15 ▲ ∞% ≫More

Mobile | Full

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map

Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved

Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.